Discover how the NPPA’s price reduction on 35 essential medicines, including diabetes, heart, and infection drugs, brings relief to patients.
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, Government of India, has implemented a significant decision to reduce the retail prices of 35 essential medicines, effective as of August 3, 2025. This initiative, notified under the Drugs (Prices Control) Order, 2013 (DPCO), aims to enhance the affordability and accessibility of critical medications for patients managing chronic and acute conditions such as cardiovascular diseases, diabetes, mental health disorders, and infections. The price reduction directly addresses the financial burden faced by patients, particularly those with long-term illnesses who spend thousands of rupees monthly on medications, offering savings on every tablet. This move aligns with the NPPA’s mandate to regulate the prices of scheduled drugs listed under the National List of Essential Medicines (NLEM) and to monitor non-scheduled drugs to ensure fair pricing practices across the pharmaceutical sector.
The price control order covers a range of formulations critical for addressing prevalent health conditions in India. Key formulations include fixed-dose combinations such as Aceclofenac, Paracetamol, and Trypsin-Chymotrypsin for pain and inflammation management; Amoxicillin and Potassium Clavulanate for bacterial infections; Atorvastatin combinations for cardiovascular health; and oral antidiabetic combinations like Empagliflozin, Sitagliptin, and Metformin for diabetes management. The order also includes pediatric formulations such as the oral suspension of Cefixime and Paracetamol, as well as supplements and injectables like Cholecalciferol (Vitamin D3) drops and Diclofenac injections. Specific price caps have been set, with a tablet containing Aceclofenac, Paracetamol, and Trypsin-Chymotrypsin priced at ₹13, while the same formulation marketed by Cadila Pharmaceuticals is capped at ₹15.01. A tablet combining Atorvastatin 40 mg and Clopidogrel 75 mg, used for cardiovascular conditions, is fixed at ₹25.61, and Cholecalciferol drops and Diclofenac injections are priced at ₹31.77 per ml.
To ensure compliance and transparency, the NPPA has mandated that all retailers and dealers prominently display the updated price lists at their premises. The NPPA has clarified that the notified prices exclude Goods and Services Tax (GST), which may be added as applicable, provided manufacturers have paid or are liable to pay GST on the retail price. Non-compliance with these prices could lead to penalties under the DPCO, 2013, and the Essential Commodities Act, 1955, including the recovery of overcharged amounts with interest. Manufacturers are required to upload updated price lists through the Integrated Pharmaceutical Database Management System (IPDMS) in Form V and notify both the NPPA and state drug controllers. The notification revokes any prior pricing directives for the specified formulations and manufacturers, ensuring clarity in the pricing structure.
This decision brings direct relief to millions of patients battling chronic illnesses, who face significant financial strain due to recurring medical expenses. The NPPA’s regulatory framework, supported by platforms like ‘Pharma Sahi Daam’ for price monitoring and ‘Pharma Jan Samadhan’ for grievance redressal, ensures that the benefits of this price reduction reach consumers effectively. By targeting formulations critical for managing cardiovascular diseases, diabetes, infections, and other conditions, the NPPA addresses the healthcare needs of a diverse patient population, reinforcing the government’s commitment to equitable healthcare and affordability across India.
Connect with us at mystory@aawaazuthao.com